Queen's University at Kingston

Bellus Health (International) Limited

Neurochem (International) Limited

The Sir Mortimer B. Davis-Jewish General Hospital

Osta Biotechnologies

Other

The Upjohn Co.

University Health Network

Neurochem, Inc.

Bellus Health Inc.

Walter A Szarek

Xianqi Kong

Donald F Weaver

Robert Kisilevsky

Ajay Gupta

David Migneault

Jason Z Vlahakis

Francine Gervais

Hyman M Schipper

Moulay Alaoui-Jamali

Kanji Nakatsu

Gregory R J Thatcher

Ian E Crandall

Boris I Gorine

Suree Narindrasorasak

Paul Fraser

John K Jones, Deceased

The present disclosure relates to certain new and known triazolium and/or imidazolium salts and to their therapeutic use, for example in methods of treating or preventing an infection by aorparasite in a subject in need thereof. The triazolium and imidazolium salts are compounds of the Formula (I) or (II): wherein R-R, R-R, R-R, X, X', X&#x2033;, Y, Y&#x2032; and Y&#x2033; are as defined in the disclosure. 

Triazolium and imidazolium salts and uses thereof

Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumor tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Substituted imidazole derivatives and methods of use thereof for treating cancer

Disclosed in certain embodiments is a method of treating and/or mitigating prostate cancer, ovarian cancer, melanoma, colorectal cancer, breast cancer or lung cancer, comprising administering to an individual in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I): 

Methods of treating cancer with imidazolyl compounds

Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

Methods and compounds for inhibiting amyloid deposits

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

Sulfonated compounds and compositions for treating amyloidosis

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.

Methods and compositions for treating amyloid-related diseases

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

Phosphono-carboxylate compounds for treating amyloidosis

Method for treating amyloidosis

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

Phosphonocarboxylate compounds for treating amyloidosis

In vivo and in vitro methods of increasing amyloid deposition using amyloid-enhancing compounds are described. Methods of forming amyloid fibrils and screening for agents useful in treating amyloidosis are also described. Animals having non-naturally occurring amyloid deposits produced using the amyloid-enhancing compounds even further are described.

Methods of increasing amyloid deposition

Growing community of inventors

Kingston, Canada

Walter A Szarek